[Asia Economy Reporter Cho Hyun-ui] Huons Global announced on the 2nd that it has completed domestic Phase 1 and Phase 3 clinical trials for the improvement of lateral canthal lines (crow's feet) using the botulinum toxin product 'Liztox' and has applied to the Ministry of Food and Drug Safety for a change in product approval.
In August 2018, Huons Global received approval from the Ministry of Food and Drug Safety for Phase 1 and Phase 3 clinical trial plans for 'improvement of moderate to severe lateral canthal lines' of Liztox, which were conducted at Chung-Ang University Hospital and Konkuk University Hospital. According to the company, in the clinical trials conducted on patients with moderate or more severe lateral canthal lines, Liztox was not inferior in efficacy compared to existing botulinum toxin products, and safety was also confirmed.
Liztox is a botulinum toxin product approved by the Ministry of Food and Drug Safety in April last year. Huons Global plans to obtain an indication for the improvement of crow's feet within this year.
Huons Global plans to further expand the indications for Liztox. The company is currently conducting a Phase 1 clinical trial for the treatment of upper limb muscle spasticity after stroke and a Phase 2 clinical trial for the improvement of benign masseter hypertrophy (square jaw), aiming for approval from the Ministry of Food and Drug Safety in 2022. In China, it has received approval for the Phase 3 clinical trial plan for the improvement of glabellar lines and is preparing for it.
Yoon Sung-tae, Vice Chairman of Huons Global, stated, "If the indication for crow's feet improvement is added, we expect significant synergy in the cosmetic field along with the improvement of glabellar lines," and added, "We will promptly complete the clinical trials for upper limb muscle spasticity and square jaw improvement to further expand our position in the domestic botulinum toxin market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
